News | December 17, 2012

European Journal of Heart Failure Lauds Biocontrol Medical’s Research on Vagus Nerve Stimulation for Treating HF

BioControl Medica Clinical Study CardioFit Vagus European Journal of Heart Failu

December 17, 2012 — BioControl Medical has announced that the pilot clinical study of its CardioFit vagus nerve stimulation system has been recognized as seminal original research in the European Journal of Heart Failure. According to a recent editorial, “the highly cited open-label phase II study [of the CardioFit] by De Ferrari et al. demonstrated for the first time that chronic vagus nerve stimulation is associated with improvements in New York Heart Association (NYHA) class, six minute walk test, left ventricular ejection fraction, and systolic volumes up to one year, setting the stage for further investigations and clinical trials in this new era of device thearapy.”[1,2]

Conducted in Italy, Germany, The Netherlands and Serbia, the multi-center pilot clinical study of the CardioFit was designed to assess the six-month safety and clinical response to the therapy in 32 patients with NYHA II-IV heart failure on optimized background medical therapy. Study data showed that patients experienced sustained significant improvement across key clinical and self-reported quality of life measures at six and 12 months.[2] Results of the original pilot study were published in the European Heart Journal in April 2011.

“It is extremely gratifying to see our work not only published in the European Heart Journal but also recognized for its impact by the European Journal of Heart Failure,” said Dr. Goran Milasinovic, a CardioFit pilot study investigator at the Clinical Center of Serbia in Belgrade. “Vagus nerve stimulation has proven to be a very exciting new area of exploration in the treatment of heart failure, with additional clinical study of its potential benefits now well underway.”

More recent clinical research on the CardioFit includes an extension of the pilot study that continued to follow 19 patients. Presented at the American Heart Association Scientific Sessions 2012 in November, the results of the extended study showed that the CardioFit’s favorable clinical effects — as demonstrated by improved hemodynamics, quality of life and six-minute walk test — were maintained in patients beyond the study’s original six- and 12-month evaluation points, up to 24 months.[3] Patient follow up now extends beyond four years, with good therapy tolerance and no reported safety issues.

In addition, the safety and efficacy of the CardioFit is being explored further in the INOVATE-HF (INcrease Of VAgal TonE in Heart Failure) global, multi-center, investigational device exemption (IDE) clinical study. Initiated in April 2011, INOVATE-HF is a prospective, randomized, controlled clinical study that will evaluate the system’s potential to reduce hospitalization and death among patients with HF, while also exploring whether combined treatment with CardioFit and prescription drug therapy is more effective than drug therapy alone.[4]

“The INOVATE-HF study is an important pivotal trial that may ultimately position vagus nerve stimulation as a valuable new therapeutic option for patients with HF,” said Douglas Mann, an INOVATE-HF study investigator at Washington University School of Medicine in St. Louis, Mo. “We are encouraged that our colleagues in Europe have validated the breakthrough nature of the earlier research and the need for additional study of the CardioFit in a broader population of patients.”

The CardioFit system consists of a stimulator, a sensor lead and a stimulation lead, which are implanted under the skin of the chest. The sensor lead is extended from the stimulator to the right ventricle of the heart, and the stimulation lead is extended from the stimulator to the vagus nerve on the right side of the neck. Once activated, the stimulator’s electrical pulses are transferred via the stimulation lead to the vagus nerve. At the same time, the sensor lead monitors changes in heart activity and turns stimulation on or off accordingly. Like a pacemaker, the CardioFit System can be programmed on and off via external wireless communication with the device.

For more information: www.biocontrol-medical.com

References

1 Luscher, TF, et al. “The European Heart Journal and the European Journal of Heart Failure: partners in scientific publishing.” European Journal of Heart Failure (2012) 14, 1075–1082

2 De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ. “Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure.” Eur Heart J (2011) 32 (7): 847-855.

3 Dennert R, et al. “Long-term Benefits of Vagal Nerve Stimulation Therapy in Heart Failure.” American Heart Association Scientific Sessions 2012.

4 Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, Starling, RC, Mann DL. “Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: INOVATE-HF.” American Heart Journal (June 2012) 163 (6): 955-962.

Related Content

anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016
News | Heart Valve Technology| May 24, 2016
Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve...
News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
cardiac rehab, cardiac rehabilitation, CHF, heart failure

Congestive heart failure patient Dorothy Moore committed herself to cardiac rehabilitation and increasing the amount of exercise she did and was able to reverse her heart failure class. Patient engagement is key to improving CHF patient quality of life and outcomes without the use of drugs and devices.

Feature | Cardiac Rehabilitation| May 24, 2016 | Karen D. Walker, RN, MSN, and Stephanie Rejc, MS
Cardiac rehabilitation and exercise training has been shown to improve clinical status and outcomes in congestive hea
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
Boston Scientific, FDA, IntelliNav XP ablation catheters, Rhythmia Mapping System

Rhythmia Mapping System image courtesy of Boston Scientific

Technology | Ablation Systems| May 23, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with...
News | Heart Failure| May 23, 2016
May 23, 2016 — In a guideline update published last week, the American College of Cardiology, American Heart Associat
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
Overlay Init